UP!
| Traded as | NYSE: DPLO S&P 600 Component |
|---|
Diplomat Pharmacy, Inc., is the largest independent specialty pharmacy in the United States. Headquartered in Flint, Michigan, Diplomat has facilities across the United States and dispenses drugs in all 50 states. Diplomat offers specialized medication and medication management programs for patients with complex and chronic conditions such as cancer, hepatitis, multiple sclerosis, HIV and others.
In October 2014, Diplomat Pharmacy launched an initial public offering (IPO) on the New York Stock Exchange after raising $173 million. Diplomat is the only publicly traded independent specialty pharmacy in the United States. Diplomat currently ranks 29th in the state of Michigan on the list of the top publicly traded companies based on revenues.
Diplomat distributes oncology medications in a CarePak™, specially designed to improve patient adherence. Diplomat also serves as the specialty pharmacy for many retail pharmacies, hospitals and health systems throughout the United States.
Diplomat is accredited by several third-party agencies, including URAC, the American Society of Health-System Pharmacists, and the Accreditation Commission for Health Care.
For hemophilia and other blood disorder patients, they offer in-home and outpatient specialty infusion services.
Dale Hagerman founded Diplomat Pharmacy in 1975 in Flint, Michigan. For over 40 years, Diplomat has been working with patients living with chronic diseases. In 2009, Diplomat moved its headquarters back to Flint from Swartz Creek, Michigan. In 2014, Diplomat ranked 69th on the Inner City 100 list of fastest growing companies based in inner cities.
In July 2014, Diplomat acquired MedPro Rx, a specialty pharmacy based in North Carolina.
In February 2015, Diplomat acquired BioRx, a specialty pharmacy in Cincinnati, Ohio for $315 million. According to documents filed with the Securities and Exchange Commission, the purchase "added significant scale to [Diplomat's] specialty infusion services.
In June 2015, Diplomat acquired Philadelphia-based Burman’s Specialty Pharmacy for $73 million, growing their geographic presence.
On October 9, 2017, co-founder Dale Hagerman died at the age of 90.
| 2016-06-23 | Initiated Coverage | Cowen and Company | Market Perform | $37.00 |
| 2016-06-08 | Initiated Coverage | Bank of America | Hold | |
| 2016-06-08 | Initiated Coverage | Bank of America Corp. | Hold | |
| 2016-06-07 | Reiterated Rating | Bank of America | Neutral | |
| 2016-06-01 | Initiated Coverage | Barclays | Overweight | $41.00 |
| 2016-06-01 | Initiated Coverage | Barclays PLC | Overweight | $41.00 |
| 2016-05-19 | Reiterated Rating | William Blair | Outperform | |
| 2016-05-18 | Reiterated Rating | Credit Suisse | Hold | |
| 2016-05-18 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-05-11 | Boost Price Target | Mizuho | Neutral | $30.00 to $33.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo | Hold | |
| 2016-05-10 | Reiterated Rating | Leerink Swann | Buy | $35.00 to $36.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo & Co. | Hold | |
| 2016-04-18 | Initiated Coverage | Avondale Partners | Outperform | $38.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse | Neutral | $29.00 |
| 2016-03-01 | Reiterated Rating | Leerink Swann | Outperform | $40.00 to $35.00 |
| 2016-03-01 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $52.00 to $30.00 |
| 2016-03-01 | Downgrade | Mizuho | Buy to Neutral | $53.00 to $30.00 |
| 2016-01-06 | Initiated Coverage | Barclays | Overweight to Overweight | $41.00 |
| 2015-11-04 | Lower Price Target | Raymond James | Outperform | $55.00 to $45.00 |
| 2015-11-04 | Reiterated Rating | Leerink Swann | Outperform | $35.00 to $40.00 |
| 2015-11-04 | Lower Price Target | Raymond James Financial Inc. | Outperform | $55.00 to $45.00 |
| 2015-10-22 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-10-21 | Lower Price Target | Mizuho | Buy | $53.00 to $44.00 |
| 2015-10-14 | Upgrade | Bank of America | Underperform to Neutral | $32.00 |
| 2015-10-02 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $58.00 to $31.00 |
| 2015-09-23 | Reiterated Rating | William Blair | Buy | |
| 2015-08-04 | Boost Price Target | Leerink Swann | Outperform | $40.00 to $55.00 |
| 2015-07-19 | Downgrade | Bank of America | Sell | |
| 2015-07-16 | Initiated Coverage | Bank of America | Underperform | $38.00 |
| 2015-07-10 | Reiterated Rating | Morgan Stanley | Buy | |
| 2015-07-09 | Reiterated Rating | William Blair | Outperform | |
| 2015-07-09 | Initiated Coverage | Morgan Stanley | Overweight | $41.00 to $56.00 |
| 2015-06-29 | Initiated Coverage | Mizuho | Buy | $53.00 |
| 2015-06-22 | Boost Price Target | Robert W. Baird | Outperform | $40.00 to $50.00 |
| 2015-06-05 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $39.00 to $46.00 |
| 2015-05-27 | Initiated Coverage | Raymond James | Outperform | $43.00 |
| 2015-05-12 | Reiterated Rating | Robert W. Baird | Outperform | $38.00 to $40.00 |
| 2015-05-12 | Set Price Target | Leerink Swann | Buy | $36.00 to $40.00 |
| 2015-05-12 | Boost Price Target | Credit Suisse | Outperform | $37.00 to $40.00 |
| 2015-04-23 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $41.00 |
| 2015-03-03 | Set Price Target | Credit Suisse | Buy | $37.00 |
| 2015-01-27 | Initiated Coverage | Robert W. Baird | Outperform | $32.00 |
| 2015-01-08 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $28.00 to $31.00 |
| 2014-11-19 | Initiated Coverage | Morgan Stanley | Equal Weight | $26.00 |
| 2014-11-19 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $28.00 |
| 2014-11-19 | Initiated Coverage | William Blair | Outperform | |
| 2014-11-19 | Initiated Coverage | Credit Suisse | Outperform | |
| 2014-11-19 | Initiated Coverage | Leerink Swann | Outperform | $30.00 |
| 2016-06-23 | Initiated Coverage | Cowen and Company | Market Perform | $37.00 |
| 2016-06-08 | Initiated Coverage | Bank of America | Hold | |
| 2016-06-08 | Initiated Coverage | Bank of America Corp. | Hold | |
| 2016-06-07 | Reiterated Rating | Bank of America | Neutral | |
| 2016-06-01 | Initiated Coverage | Barclays | Overweight | $41.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In DPLO 24 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| JANUS CAPITAL MANAGEMENT LLC | 5.36M |
| BlackRock Fund Advisors | 3.78M |
| BlackRock Institutional Trust Company, N.A. | 1.14M |
| WEATHERBIE CAPITAL, LLC | 0.54M |
| OPPENHEIMER FUNDS INC | 0.48M |
| BlackRock Investment Management, LLC | 0.23M |
| CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. | 0.19M |
| RUSSELL FRANK CO/ | 0.13M |
| TIAA CREF INVESTMENT MANAGEMENT LLC | 0.12M |
| TEACHERS ADVISORS INC | 0.12M |
| Iguana Healthcare Management, LLC | 100000 |
| BLACKROCK ADVISORS LLC | 83020 |
| BlackRock Group LTD | 81640 |
| PEAK6 Investments, L.P. | 56800 |
| KCG Holdings, Inc. | 42985 |
UM